argenx wins EMA CHMP nod for subcutaneous Vyvgart in myasthenia gravis
The positive opinion relied on a comparator study that showed the subcutaneous version was non-inferior to the intravenous one.
The positive opinion relied on a comparator study that showed the subcutaneous version was non-inferior to the intravenous one.
What's Your Reaction?
